Novel HIV Vaccine Shows Potential in Infected Rhesus Macaques

Researchers have developed an anti-HIV vaccine that has shown promising results in rhesus macaques. Previous research has established the need for an anti-HIV vaccine to induce polyclonal neutralizing antibodies (nABs) that some HIV-infected individuals produce naturally. In this study, polyclonal neutralizing antibodies from a person living with HIV were isolated and used to develop a novel vaccine. The study CH505 immunogen was derived from the HIV-infected living human.

HIV-1 CH505 envelope trimer with a Toll-like receptor 7/8 agonist-induced potent HIV-1 polyclonal neutralizing antibodies. The required serum dilution for neutralizing 50% virus replication (ID50 titer) to protect 90% of macaques was 1:364 against challenge virus growth in rhesus CD4+ T cells. On structural analysis of the vaccine-induced nABs, targeting of Env CD4 binding site or N156 glycan and the third variable…